Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
May 2018
-
Machine learning poised to accelerate drug discovery
Technology used to tag friends on social media could change the way drug discovery is done.
-
Media Release
Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
Alcon Cares to donate 100 reprocessed Infiniti® units to clinics helping underserved patients in Asia, Central and South America, and Africa over the next three years Program to increase… -
Media Release
AveXis Reports First Quarter 2018 Financial and Operating Results
-- Significant progress across operating functions including licensing, clinical trials and regulatory interactions -- -- AVXS-101 pre-BLA meeting with FDA is scheduled to be… -
Key Release
Sandoz receives complete response letter from the US FDA for proposed biosimilar rituximab
Holzkirchen, May 2, 2018 - Sandoz, a Novartis division, announced today that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the Biologics Licensing… -
T.J. Sharpe on why clinical trials matter
Melanoma survivor T.J. Sharpe discusses the importance of clinical trials to help raise awareness among the community.
-
Media Release
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Kymriah demonstrated an overall response rate of 50%, with median duration of response not yet reached at the time of data cut-off, indicating sustainability of response[1] Kymriah is the only… -
Key Release
Novartis provides update on proposed acquisition of AveXis
Basel, May 1, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act") applicable to…
April 2018
-
Media Release
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
Tafinlar + Mekinist is the first oral targeted adjuvant combination therapy to demonstrate significant clinical benefit in patients with a BRAF V600 mutation, following complete surgical resection… -
Media Release
New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week… -
In The News
How Long Till the Final World Malaria Day?
Deaths from malaria have been driven down by 60% since 2000. But unchecked drug resistance could cause more than 100,000 new deaths each year. Vas Narasimhan, CEO of Novartis, explains how we could… -
Media Release
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening… -
Media Release
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible Using patients' self-recorded measurements, FocalView aims to…
Pagination
- ‹ Previous page
- 1
- …
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- …
- 154
- › Next page
Test disclaimer...!!!